New Vaccine Platforms (NVP) Program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Health and Human Services (HHS), specifically the OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE, has issued a Special Notice for the New Vaccine Platforms (NVP) Program. This program aims to identify and advance novel vaccine platforms for the BARDA medical countermeasure (MCM) portfolio, focusing on technologies that are safe, effective across multiple infectious disease threats, and enable efficient development and manufacturing. The program is based in Washington, DC.
Program Purpose & Scope
The NVP Program seeks to identify new vaccine platforms for the BARDA MCM portfolio. The goal is to advance these platforms through a staged capability demonstration to identify technologies that are:
- Safe.
- Effective across multiple infectious disease threats from different pathogen families.
- Capable of enabling efficient development and manufacturing.
In-scope platform technologies notionally include protein, viral vector, and bacterial vector-based approaches that have demonstrated manufacturing of Phase 1 clinical trial material (CTM). The Request for Project Proposals is expected to be open to Offerors that are either (1) a single organization with a full technology solution or (2) a two-part team combining an antigen expression capability (Capability A) and a vaccine carrier/formulation capability (Capability B).
Program Objectives & Demonstration
The objective is to conduct a staged capability demonstration (CD) across at least two (2) emerging infectious disease (EID) threats. The CD stages include:
- CD-1: Manufacturing demonstration (all work from start to Phase 1 CTM).
- CD-2: Nonclinical demonstration (all critical path activities to support a Phase 1 IND; e.g., safety, immunogenicity, efficacy).
- CD-3: Clinical demonstration (Phase 1 trial).
Threat options are informed by BARDA's mission and the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) priority biological threats, including select EID families. Initial demonstration options notionally include Lassa virus, Nipah virus, chikungunya virus, or West Nile virus. Additional options may include a to-be-determined (TBD) pandemic influenza target and a TBD infectious disease threat aligned to the BARDA CBRN Division mission.
Significance
Advancing safe, broadly protective, and efficiently developed vaccine platforms will help ensure the U.S. MCM portfolio is optimally positioned to respond efficiently and effectively to national health security incidents.
Program Details
- Type: Special Notice (Program Announcement)
- Department/Agency: Health And Human Services / OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
- Set-Aside: None specified
- Published: March 26, 2026
- Response Due: Not specified (This is a program announcement, not a solicitation for immediate proposals)
Contact Information
- Primary: Erin Greninger, Contracting Officer (erin.greninger@hhs.gov)
- Secondary: Rebecca Harmon (rebecca.harmon@ati.org, 843-760-3358)